The COO of RNAi specialist Alnylam was critical of Big Pharma in the wake of Novartis' decision to slam the breaks on its RNAi research. The news made investors nervous about the future of the promising, but nascent technology and Alnylam stock price is down more than 20% in the last week.
Here at FierceDrugDelivery, we write often about innovations in nanotechnology as it becomes more and more important in the delivery field. These advances are mostly in the very early stages, but they're still promising as the delivery field moves even further into the nanoscale. Last year's report highlighted some companies that have since made an even bigger impact in biotech as a whole, including the newly public Bind Therapeutics and hot RNAi specialist Alnylam. You'll see familiar names in both the industry and the academic realm in this year's report, among others that have offered important developments to the arena. Check out the report >>
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year's project on the influentials.
POPULAR COMMENT THREADS
At MIT, researchers have developed nanoparticles that can carry as many as three cancer drugs at a time in a precise ratio.
A team of scientists from Oregon State University and Aradigm, a small pulmonary device company out of California, touted successful in vitro results for its inhaled, encapsulated ciproflaxacin treatment for infections associated with the lungs.
In an effort to localize the effects of anesthesia, researchers have turned to magnetic nanoparticles to target the delivery of ropivacaine in a proof-of-concept animal study.
Pennsylvania wound-care specialist Alliqua pulled in $15 million from a private funding round and another $5.3 million from the exercise of warrants, giving the company a $20.3 million windfall overall.
As drug delivery becomes more and more dependent on nanotechnology for treatments such as chemotherapy, it's important that scientists in the field understand the implications of the tiny vehicles and what factors might play a part, for good or bad, in their delivery potential.
Researchers at the University at Buffalo have put the "pop" into drug delivery by releasing compounds from liposomes called nanoballoons that break open upon being hit with a laser.
From Our Sister Sites
The FDA has lifted a clinical hold placed on a study at Memorial Sloan-Kettering of Juno Therapeutics' cutting-edge approach to treating cancer using genetically tailored T cells, FierceBiotech has learned.
Drugmakers received the first slice of FDA social media guidance in January, and now the FDA's mailbag is filling up with letters on First Amendment protections, "jurisdictional creep" and other topics from the likes of Pfizer and PhRMA.